Role of microparticles in atherothrombosis / Rosa Suades Soler; (2016), nº 84
noviembre - 2016
Sumario
ACKNOWLEDGMENTS
PREFACE
SUMMARY
RESUMEN
1. INTRODUCTION
1.1. CARDIOVASCULAR DISEASE
1.2. CELL-DERIVED MICROPARTICLES
1.3. CONCLUDING REMARKS AND UNRESOLVED ISSUES
REFERENCES
2. HYPOTHESIS AND OBJECTIVES
3. MATERIALS AND METHODS
3.1. STUDY DESIGN
3.2. CLINICAL STUDY POPULATIONS
3.3. BLOOD SAMPLING AND CLINICAL DETERMINATIONS
3.4. MICROPARTICLE ISOLATION
3.5. FLOW CYTOMETRY OF CIRCULATING MICROPARTICLES
3.6. FUNCTIONAL STUDIES
3.7. DIFFERENTIAL PROTEOMICS STUDIES
3.8. MICRORNA ANALYSIS
3.9. VALIDATION TECHNIQUES
3.10. IN SILICO BIOINFORMATIC ANALYSES
3.11. STATISTICAL ANALYSES
REFERENCES
4. RESULTS
Article 1. Circulating and platelet-derived microparticles In human blood enhance thrombosis on atherosclerotic plaques
Article 2. Lipid-lowering therapy with statins reduces microparticles shedding from endothelium, platelets and inflammatory cells
Article 3. Circulating CD45+/CD3+ lymphocyte-derived microparticles map lipid-rich atherosclerotic plaques in FH patients
Article 4. High levels of TSP1+/CD142+ platelet-derived microparticles characterise young patients with high cardiovascular risk and subclinical atherosclerosis
Article 5. Growing thrombi release increased levels of CD235a+ microparticles and decreased levels of activated platelet-derived microparticles. Validation in ST-elevation myocardial infarction patients
Article 6. Circulating microparticle signature in coronary and peripheral blood of ST elevation myocardial infarction patients in relation to pain-to-PCI elapsed time
Article 7. Microparticles from thrombin-induced platelets have a complex proteomic profile rich in prothrombotic components
Article 8. Exosomal microRNA signature predicts future ischemic events in hypercholesterolemic patients
5. DISCUSSION
6. CONCLUSIONS